Merck Data Could Support Use Of PD-L1 Biomarker In Lung Cancer
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Data suggest the biomarker could be useful in lung cancer to help identify the 25% of patients who benefit the most, according to data presented at the American Association for Cancer Research meeting. But the biomarker looks less useful in melanoma.